Promacta Global Market Report 2025

Promacta (eltrombopag) is an oral thrombopoietin receptor agonist (TPO-RA) designed to stimulate platelet production in patients with specific blood disorders. It is primarily prescribed for conditions where platelet production is insufficient, increasing the risk of bleeding. By boosting platelet levels, Promacta helps reduce bleeding risk in affected patients.

The primary indications for Promacta include chronic immune thrombocytopenia, severe aplastic anemia, hepatitis C-associated thrombocytopenia, and other related conditions. Chronic immune thrombocytopenia (ITP) is a persistent autoimmune disorder that leads to low platelet levels, resulting in excessive bleeding and requiring treatments to suppress immunity or enhance platelet production. Promacta is available in various dosage forms, such as tablets and oral suspension, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The promacta market research report is one of a series of new reports from The Business Research Company that provides promacta market statistics, including the promacta industry global market size, regional shares, competitors with the promacta market share, detailed promacta market segments, market trends, and opportunities, and any further data you may need to thrive in the promacta industry. This promacta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The promacta market size has grown strongly in recent years. It will grow from $3.79 billion in 2024 to $4.11 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to the increasing prevalence of immune thrombocytopenic purpura (ITP), a decrease in platelet counts, a growing incidence of illnesses including aplastic anemia and immune thrombocytopenia, a growing movement to enhance patient education, and a rise in healthcare expenditure.

The promacta market size is expected to see strong growth in the next few years. It will grow to $5.65 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to an increase in research and development, growing governmental efforts, an increasing global geriatric population, a growing movement to enhance patient education, an emphasis on patient assistance programs, growing healthcare infrastructure, and disposable incomes. Major trends in the forecast period include the creation of generic alternatives and biosimilars, a growing focus on patient-centric care, advancements in biotechnology and pharmaceuticals, the adoption of telemedicine and remote monitoring, and ongoing clinical trials and research initiatives.

The forecast of 8.3% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. access to Promacta by inflating prices of active pharmaceutical ingredients (APIs) manufactured in India and China, resulting in treatment delays for thrombocytopenia and higher hematology specialty costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of aplastic anemia is anticipated to drive the expansion of the promacta market in the coming years. Aplastic anemia is a rare condition where the bone marrow fails to produce enough blood cells, leading to fatigue, infections, and a heightened risk of bleeding. Various factors contribute to the prevalence of aplastic anemia, including exposure to toxic chemicals, certain medications, viral infections, autoimmune disorders, and genetic predisposition. Promacta aids in stimulating bone marrow stem cells to generate blood cells, thereby increasing platelet, red blood cell, and neutrophil counts. This reduces the need for transfusions and lowers the risk of bleeding and infections in individuals affected by aplastic anemia. For example, in April 2024, Anthony Nolan, a UK-based charity specializing in leukemia and hematopoietic stem cell transplantation, reported that approximately 100 to 150 individuals in the UK are diagnosed with aplastic anemia each year. As a result, the rising prevalence of this condition is fueling the growth of the promacta market.

The expansion of the promacta market is also being driven by increased healthcare expenditure. Healthcare expenditure encompasses the total cost of medical services, treatments, and infrastructure aimed at maintaining and improving public and individual health. Several factors contribute to rising healthcare expenditures, including an aging population, advancements in medical technology, and broader health insurance coverage. Increased healthcare spending enhances patient access to innovative treatments for thrombocytopenia and other blood disorders, while also improving diagnostic capabilities, enabling early detection, and promoting the adoption of promacta. For instance, in December 2023, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported that US healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, marking an acceleration from the 3.2% increase observed in 2021. This upward trend in healthcare expenditure is contributing to the growth of the promacta market.

The growing geriatric population is playing a significant role in the expansion of the promacta market. Individuals aged 65 and older often require specialized medical care to address age-related health concerns. The rise in the elderly population is attributed to increasing life expectancy, advancements in healthcare, declining birth rates, and improvements in medical treatments. Promacta benefits older adults by stimulating platelet production in those with blood disorders, reducing the risk of bleeding, enhancing immune function, and improving overall treatment outcomes. For example, in January 2024, the Population Reference Bureau, a Kenya-based nonprofit organization, projected that the number of Americans aged 65 and older would rise from 58 million in 2022 to 82 million by 2050. Consequently, the expanding geriatric population is a key factor driving the growth of the promacta market.

The key player in the promacta market is Novartis AG.

North America was the largest region in the promacta market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in promacta report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the promacta market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The promacta market consists of sales of extended-release tablets and powder for suspension. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Promacta Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on promacta market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for promacta ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The promacta market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Chronic Immune Thrombocytopenia; Severe Aplastic Anemia; Hepatitis C-associated Thrombocytopenia; Other Indications
• 2) By Dosage Form: Tablets; Oral Suspension
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Chronic Immune Thrombocytopenia (ITP): Primary Immune Thrombocytopenia; Secondary Immune Thrombocytopenia
• 2) By Severe Aplastic Anemia: Adult Severe Aplastic Anemia; Pediatric Severe Aplastic Anemia
• 3) By Hepatitis C-associated Thrombocytopenia: Genotype 1 Hepatitis C-associated Thrombocytopenia; Genotype 2 Hepatitis C-associated Thrombocytopenia; Genotype 3 Hepatitis C-associated Thrombocytopenia
• 4) By Other Indications: Myelodysplastic Syndromes (MDS); Bone Marrow Disorders; Radiation-Induced Thrombocytopenia
• Companies Mentioned: Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.